Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Invion ( (AU:IVX) ).
Invion Limited has notified the market of the issue of 200,000 unquoted options under its employee incentive scheme, exercisable at $0.12 and expiring on 27 February 2029. The new options, which are not intended to be quoted on the ASX, reflect the company’s continued use of equity-based incentives to retain and motivate staff, modestly increasing potential future dilution while aligning employees’ interests with long-term shareholder value.
The issuance of these unquoted options underscores Invion’s strategy of rewarding key personnel through performance-linked securities rather than immediate cash outlays. This approach can help conserve cash resources for research, development and operational activities, while giving employees upside exposure to the company’s share price performance over the medium term.
The most recent analyst rating on (AU:IVX) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Invion stock, see the AU:IVX Stock Forecast page.
More about Invion
Invion Limited is an Australia-based company listed on the ASX under the code IVX. The company operates within the life sciences and biotechnology sector, focusing on the development and commercialisation of medical technologies and therapies for healthcare markets.
Average Trading Volume: 117,819
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$7.37M
For an in-depth examination of IVX stock, go to TipRanks’ Overview page.